A revolutionary therapeutic approach for psoriasis: Bispecific biological agents

Expert Opinion on Investigational Drugs

Volumn 25, Issue 7, 2016, Pages 751-754

  Torres, T ^a   Romanelli, M ^b   Chiricozzi, Andrea ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

ABT 122; ALX 0761; AZ17; Bimekizumab; bispecific antibodies; COVA322; Psoriasis

Indexed keywords

ABT 122; ADALIMUMAB; ALX 0761; ANTIPSORIASIS AGENT; AZ 17; BIMEKIZUMAB; BIOLOGICAL PRODUCT; BISPECIFIC ANTIBODY; BLINATUMOMAB; CATUMAXOMAB; COVA 322; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; NI 1401; PROTEIN KINASE FYN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UCB 4940; UNCLASSIFIED DRUG; BIOLOGICAL FACTOR;

ADAPTIVE IMMUNITY; ANTIBODY AFFINITY; ANTIINFLAMMATORY ACTIVITY; EDITORIAL; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INNATE IMMUNITY; MONOTHERAPY; PATIENT; PHARMACEUTICAL CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLASMA HALF LIFE; PROTEIN DEGRADATION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; SEQUENCE HOMOLOGY; TREATMENT RESPONSE; IMMUNOLOGY;

ANTIBODIES, BISPECIFIC; BIOLOGICAL FACTORS; HUMANS; PSORIASIS;

EID: 84969759480     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1187130     Document Type: Editorial

References (22)

1. E.C.Levin, R.Gupta, G.Brown, et al. Biologic fatigue in psoriasis. J Dermatolog Treat. 2014;25:78–82.
2. A.Chiricozzi, D.Caposiena, V.Garofalo, et al. A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast. Expert Rev Clin Immunol. 2016 Mar;12:237–249.
3. A.Chiricozzi, E.Guttman-Yassky, M.Suarez-Farinas, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677–687.• Study investigating intimate interactions between IL-17A and TNF-α.
4. M.A.Lowes, C.B.Russell, D.A.Martin, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–181.
5. J.G.Krueger, S.Fretzin, M.Suárez-Fariñas, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130:145–154.
6. C.E.M.Griffiths, K.Reich, M.Lebwohl, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.•• Head-to-head phase III trial testing ixekizumab (anti-IL-17 agents) vs. etanercept (anti-TNF agent).
7. D.Thaçi, A.Blauvelt, K.Reich, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.•• Head-to-head phase III trial testing secukinumab (anti-IL-17 agents) vs. ustekinumab (anti-p40IL-12/IL-23 agent).
8. A.Chiricozzi, K.E.Nograles, L.M.Johnson-Huang, et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One. 2014;9:e90284.
9. L.C.Zaba, I.Cardinale, P.Gilleaudeau, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–3194.• Study demonstrating the link between etanercept efficacy and Th17 pathway.
10. L.C.Zaba, M.Suárez-Fariñas, J.Fuentes-Duculan, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124:1022–1395.• Study on etanercept efficacy that is linked to the suppression of IL-17 signaling, and not to TNF-α.
11. A.Johnston, A.M.Guzman, W.R.Swindell, et al. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol. 2014;171:97–107.
12. A.G.Hendriks, H.M.van der Velden, E.A.Wolberink, et al. The effect of adalimumab on key drivers in the pathogenesis of psoriasis. Br J Dermatol. 2014;170:571–580.
13. M.Silacci, W.Lembke, R.Woods, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8:141–149.
14. K.Vanheusden, L.Detalle, A.Hemeryck, et al. Pre-clinical proof-of-concept of ALX-0761, a nanobody neutralising both IL-17A and IL-17F in a cynomolgus monkey collagen induced arthritis model. Poster n. 1287, presented at the Annual Meeting of the American College of Rheumatology (ACR); 2013 Oct 26–30; San Diego, CA.• Preclinical proof-of-concept study on ALX-0761.
15. K.Stenderup, C.Rosada, K.Shanebeck, et al. AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use-improves psoriasis in a human xenograft transplantation model. Protein Eng Des Sel. 2015;28:467–480.• Preclinical proof-of-concept study on AZ17.
16. A.C.Chan, P.J.Carter Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10:301–316.
17. R.Mabry, D.G.Gilbertson, A.Frank, et al. A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo. MAbs. 2010;2(1):20–34.
18. M.Weinblatt, M.Schiff, A.Goldman, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2006;66:228–234.
19. M.C.Genovese, S.Cohen, L.Moreland, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412–1419.
20. J.A.Fischer, A.J.Hueber, S.Wilson, et al. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol. 2015;67:51–62.
21. L.Puig. PASI90 response: the new standard in the therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
22. S.Glatt, E.Helmer, F.Strimenopoulou, et al. First-in-human IL-17A and IL-17F blockade with bimekizumab in patients with mild-to-moderate psoriasis: results of a randomized, placebo-controlled, single-dose-escalating study. 74th Annual Meeting American Academy of Dermatology; Washington, DC, 2016 Mar 4–8. Abstract F053.